Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Closes $1M Bridge Loan

Premium

MDRNA said last week that it has closed a $1 million bridge loan worth $1 million.

Under the terms of the loan, the company sold $1 million in promissory notes and issued warrants to certain accredited investors to purchase an aggregate of about 1.1 million of its shares at $1.02 per share.

"This bridge loan provides us with the flexibility to pursue partnering and financing options into the beginning of next year," MDRNA President and CEO Michael French said in a statement. "As we continue to execute on our business strategy, this ensures that we have sufficient resources to achieve our near-term objectives."

The loan will become due and payable on February 1, 2010, with interest calculated at 12 percent annually and payable on the due date, MDRNA said. The loan is to be secured against the assets of MDRNA and its subsidiaries.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.